These data suggest that the effect of Efnb2-shRNA treatment was primarily due to changes in astrocytes and that astrocyte expression is the likely mechanism underlying ephrinB2’s action in mutant SOD1-associated ALS. This evidence concerns the gene EFNB2 and amyotrophic lateral sclerosis.